Overview

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mustang Bio
Treatments:
Cyclophosphamide
Decitabine
Fludarabine
Fludarabine phosphate